Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Next Science Ltd ( (AU:NXS) ) has provided an announcement.
Next Science Limited reported a slight decline in product sales for the first quarter of FY25, with total sales of US$5.3 million, a 3% decrease from the prior corresponding period. Despite a significant increase in direct sales of XPERIENCE and BLASTX products, the overall sales were impacted by a decline in Durable Medical Equipment (DME) sales. The company maintained a strong gross margin of 84%, attributed to a favorable product mix. Additionally, Next Science addressed an FDA Warning Letter, ensuring that their products remain safe and effective for their intended uses, and continued to focus on achieving a positive cash flow position.
More about Next Science Ltd
Next Science Limited is a medical technology company focused on commercializing its proprietary XBIO suite of products aimed at reducing the impact of biofilm-based infections in human health.
YTD Price Performance: -28.57%
Average Trading Volume: 6,181
Technical Sentiment Signal: Buy
Current Market Cap: $18.69M
See more data about NXS stock on TipRanks’ Stock Analysis page.